GH Stock Overview
A precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Guardant Health, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$31.57 |
52 Week High | US$38.53 |
52 Week Low | US$15.81 |
Beta | 1.26 |
1 Month Change | -3.31% |
3 Month Change | 41.57% |
1 Year Change | 10.58% |
3 Year Change | -67.12% |
5 Year Change | -59.60% |
Change since IPO | -1.96% |
Recent News & Updates
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher
Nov 08An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued
Oct 25Recent updates
Market Participants Recognise Guardant Health, Inc.'s (NASDAQ:GH) Revenues Pushing Shares 36% Higher
Nov 08An Intrinsic Calculation For Guardant Health, Inc. (NASDAQ:GH) Suggests It's 44% Undervalued
Oct 25Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 24Guardant Health: Top-Line Growth Undeniable, Compounding Ability Remains Unseen
Aug 21Guardant Health, Inc.'s (NASDAQ:GH) P/S Is Still On The Mark Following 26% Share Price Bounce
Jul 31Guardant Health, Inc. (NASDAQ:GH) Shares Could Be 49% Below Their Intrinsic Value Estimate
Jul 12Guardant: Double-Digit Sales Projections Come At A Cost
Jun 06Is Now The Time To Look At Buying Guardant Health, Inc. (NASDAQ:GH)?
Jun 04Investors Appear Satisfied With Guardant Health, Inc.'s (NASDAQ:GH) Prospects As Shares Rocket 31%
May 14Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Mar 29With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For
Jan 21Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Nov 20Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?
Sep 26A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)
Sep 05Is Guardant Health (NASDAQ:GH) A Risky Investment?
Aug 15A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)
May 28Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?
Apr 05Is Guardant Health (NASDAQ:GH) Using Too Much Debt?
Dec 28Shareholder Returns
GH | US Healthcare | US Market | |
---|---|---|---|
7D | -9.4% | -0.2% | -2.2% |
1Y | 10.6% | -9.4% | 23.9% |
Return vs Industry: GH exceeded the US Healthcare industry which returned -9.4% over the past year.
Return vs Market: GH underperformed the US Market which returned 23.9% over the past year.
Price Volatility
GH volatility | |
---|---|
GH Average Weekly Movement | 8.3% |
Healthcare Industry Average Movement | 7.6% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 17.0% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GH's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 1,774 | Helmy Eltoukhy | guardanthealth.com |
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection.
Guardant Health, Inc. Fundamentals Summary
GH fundamental statistics | |
---|---|
Market cap | US$3.90b |
Earnings (TTM) | -US$512.41m |
Revenue (TTM) | US$692.26m |
5.6x
P/S Ratio-7.6x
P/E RatioIs GH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GH income statement (TTM) | |
---|---|
Revenue | US$692.26m |
Cost of Revenue | US$274.72m |
Gross Profit | US$417.53m |
Other Expenses | US$929.94m |
Earnings | -US$512.41m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -4.15 |
Gross Margin | 60.31% |
Net Profit Margin | -74.02% |
Debt/Equity Ratio | -1,900.1% |
How did GH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 22:03 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Guardant Health, Inc. is covered by 30 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Michael Ryskin | BofA Global Research |
Derik de Bruin | BofA Global Research |
Mark Massaro | BTIG |